Trevi Therapeutics (TRVI) Tops Q2 EPS by 1c
Tweet
Share
E-mailGet Alerts TRVI Hot Sheet
Join SI Premium – FREE
Trevi Therapeutics (NASDAQ: TRVI) reported Q2 EPS of ($0.09), $0.01 better than the analyst estimate of ($0.10).
For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Keefe, Bruyette & Woods Downgrades Bain Capital Specialty Finance (BCSF) to Market Perform
- Raymond James Downgrades Accelerant Holdings (ARX) to Market Perform
- Keefe, Bruyette & Woods Downgrades Crescent BDC (CCAP) to Market Perform
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
